A recent court decision has ostensibly made if possible for generic-drug companies to manufacture their own versions of the fish oil pill Lovaza. How does this news affect shareholders of GlaxoSmtihKline (GSK), the company that sells the drug in the U.S., and how can this decision affect rivals like struggling biotech company Amarin (AMRN -1.20%)?
Analysts David Williamson and Max Macaluso discuss these topics in the following video segment from The Motley Fool's health-care show Market Checkup.
